Australian company Telix has announced that the first patient has been dosed in a Phase 1 study of its investigational targeted radiation therapy, TLX250, combined with Merck's DNA-dependent protein kinase inhibitor candidate, peposertib. …
First patient dosed in study of Telix's TLX250 with Merck's peposertib
July 19, 2023 Australian Biotech
Latest Video
New Stories
-
Just because the system involves humans, it does not make it human
August 14, 2025 - - Latest News -
Australian company Mirugen secures backing to process cell technology
August 13, 2025 - - Latest News -
AccessCR’s awards celebrate partnerships between lived experience and science
August 13, 2025 - - Latest News -
Firebrick says Nasodine COVID-19 patent accepted in Europe
August 13, 2025 - - Australian Biotech -
Orthocell advances US rollout of nerve repair product Remplir
August 13, 2025 - - Australian Biotech -
AVITA Medical successfully completes Australian equity raise
August 13, 2025 - - Australian Biotech -
Experienced innovation leader joins AusBiotech as its Head of Investment
August 13, 2025 - - Australian Biotech